Viewing Study NCT02542423



Ignite Creation Date: 2024-05-06 @ 7:30 AM
Last Modification Date: 2024-10-26 @ 11:49 AM
Study NCT ID: NCT02542423
Status: UNKNOWN
Last Update Posted: 2015-09-07
First Post: 2015-09-01

Brief Title: Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure
Sponsor: Centre Hospitalier Universitaire de Besancon
Organization: Centre Hospitalier Universitaire de Besancon

Study Overview

Official Title: Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure The ENDOLUNG Study
Status: UNKNOWN
Status Verified Date: 2015-09
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: According to literature data Endocan can detect the onset of respiratory failure The investigators aim to prove its value also for cardiac surgery patients
Detailed Description: Endocan is an endothelium derived soluble dermatan sulfate proteoglycan Literature data shows that alterate levels of its blood concentration correlate with the onset of pulmonary failure in patients with major trauma and septic shock

In cardiac surgery respiratory failure and infections are threatening complications leading to mortality rates up to 80 A rapid diagnosis and treatment of this pathology is crucial to improve the clinical outcome

Unfortunately specific data for the efficacy of Endocan predictive value in cardiac surgery patients are not available

The investigators aim to determinate if Endocan can be a helpful tool to identify patients developing acute respiratory failure after cardiac surgery and anticipate specific treatment in order to improve survival

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None